User login
Key clinical point: Galcanezumab significantly improved migraine-related outcomes in patients with high-frequency episodic migraine (HFEM) or chronic migraine, with a large proportion of patients experiencing improvements in photophobia mostly within the first month of treatment.
Major finding: Galcanezumab significantly improved headache days, migraine days, analgesics consumption, Migraine Disability Assessment scores, and Headache Impact Test-6 scores at 3 and 6 months (all P < .0001). Overall, 68.1% of patients experienced a significant improvement in ictal photophobia, of which 56.3% of patients reported an improvement within the first month of treatment.
Study details: This retrospective observational study included 47 patients with HFEM or chronic migraine and ≥3 previous prophylactic treatment failures who experienced moderate-to-severe photophobia during migraine attacks and received galcanezumab.
Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.
Source: Schiano di Cola F et al. Photophobia and migraine outcome during treatment with galcanezumab. Front Neurol. 2023;13:1088036 (Jan 18). Doi: 10.3389/fneur.2022.1088036
Key clinical point: Galcanezumab significantly improved migraine-related outcomes in patients with high-frequency episodic migraine (HFEM) or chronic migraine, with a large proportion of patients experiencing improvements in photophobia mostly within the first month of treatment.
Major finding: Galcanezumab significantly improved headache days, migraine days, analgesics consumption, Migraine Disability Assessment scores, and Headache Impact Test-6 scores at 3 and 6 months (all P < .0001). Overall, 68.1% of patients experienced a significant improvement in ictal photophobia, of which 56.3% of patients reported an improvement within the first month of treatment.
Study details: This retrospective observational study included 47 patients with HFEM or chronic migraine and ≥3 previous prophylactic treatment failures who experienced moderate-to-severe photophobia during migraine attacks and received galcanezumab.
Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.
Source: Schiano di Cola F et al. Photophobia and migraine outcome during treatment with galcanezumab. Front Neurol. 2023;13:1088036 (Jan 18). Doi: 10.3389/fneur.2022.1088036
Key clinical point: Galcanezumab significantly improved migraine-related outcomes in patients with high-frequency episodic migraine (HFEM) or chronic migraine, with a large proportion of patients experiencing improvements in photophobia mostly within the first month of treatment.
Major finding: Galcanezumab significantly improved headache days, migraine days, analgesics consumption, Migraine Disability Assessment scores, and Headache Impact Test-6 scores at 3 and 6 months (all P < .0001). Overall, 68.1% of patients experienced a significant improvement in ictal photophobia, of which 56.3% of patients reported an improvement within the first month of treatment.
Study details: This retrospective observational study included 47 patients with HFEM or chronic migraine and ≥3 previous prophylactic treatment failures who experienced moderate-to-severe photophobia during migraine attacks and received galcanezumab.
Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.
Source: Schiano di Cola F et al. Photophobia and migraine outcome during treatment with galcanezumab. Front Neurol. 2023;13:1088036 (Jan 18). Doi: 10.3389/fneur.2022.1088036